Letermovir CAS 917389-32-3
Letermovir is a highly selective antiviral compound used to prevent cytomegalovirus (CMV) infection and reactivation in immunocompromised patients, especially adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation (HSCT). With a unique mechanism of action distinct from existing CMV drugs, Letermovir demonstrates strong antiviral activity with a favorable safety profile.
what's Letermovir CAS 917389-32-3 ?
Letermovir is a potent antiviral agent that selectively inhibits the human cytomegalovirus (HCMV) DNA terminase complex, a key enzyme for viral DNA packaging and replication. It represents a novel mechanism of action distinct from traditional antivirals such as ganciclovir or foscarnet, making it valuable in research, preclinical studies, and antiviral drug development.
Technical Specification
| Item | Specification |
|---|---|
| Chemical Name | Letermovir |
| CAS Number | 917389-32-3 |
| Molecular Formula | C23H21F6N5O4 |
| Molecular Weight | 572.44 g/mol |
| Appearance | White to off-white crystalline powder |
| Purity | ≥98% (HPLC) |
| Solubility | Soluble in DMSO; slightly soluble in water |
| Storage | Store at 2–8°C, protected from light |
Key Benefits of Letermovir
- Novel antiviral with unique mechanism
- High specificity for HCMV
- Reduces viral replication without host toxicity
- Supports antiviral drug development and CMV research
- High-purity API suitable for preclinical and formulation studies
Applications of Letermovir
- CMV antiviral research and preclinical studies
- Drug discovery and mechanism of action studies
- Resistance and mutation pathway research
- Pharmaceutical formulation development
- Antiviral screening platforms
Mechanism of Action
Letermovir selectively inhibits the HCMV DNA terminase complex, which is essential for viral DNA cleavage and packaging.
- Binding to UL56 Subunit
Interacts with the UL56 subunit of the terminase complex.
- Inhibition of DNA Cleavage
Prevents cleavage of concatemeric viral DNA into unit-length genomes.
- Block of DNA Packaging
Stops incorporation of viral DNA into capsids, producing non-infectious particles.
- Suppression of Viral Replication
Reduces production of infectious virions without affecting host DNA polymerases.
Summary: By targeting the terminase complex, Letermovir interferes with viral DNA maturation and assembly, thereby limiting HCMV replication.
Side Effects
Letermovir is generally well-tolerated in research and clinical contexts. Side effects are primarily mild to moderate and may include:
- Gastrointestinal: Nausea, diarrhea
- Neurological: Headache
- Respiratory: Upper respiratory tract infections
- Hepatic: Rare mild elevation of liver enzymes
- Other: Fatigue, rare hypersensitivity reactions
Comparison: Letermovir vs Ganciclovir vs Foscarnet
| Feature | Letermovir | Ganciclovir | Foscarnet |
|---|---|---|---|
| Target | HCMV DNA terminase complex | Viral DNA polymerase | Viral DNA polymerase |
| Mechanism | DNA packaging inhibitor | Nucleoside analog | Polymerase inhibitor |
| Resistance Risk | Low | Moderate | Moderate |
| Toxicity | Low | Bone marrow suppression | Renal toxicity |
| Administration | Oral | Oral/IV | IV |
FAQ
Q1: What is Letermovir used for?
A1: Letermovir is used as a selective inhibitor of HCMV replication in research and preclinical studies.
Q2: How does Letermovir work?
A2: It inhibits the HCMV DNA terminase complex, preventing viral DNA cleavage and packaging.
Q3: Can Letermovir be used in formulation studies?
A3: Yes, the API is suitable for pharmaceutical research and formulation development.
Q4: What is the purity of this Letermovir API?
A4: The supplied material has a purity of ≥98% (HPLC verified).
Q5: Is Letermovir cytotoxic?
A5: Letermovir is selective for viral enzymes and shows minimal toxicity to host cells in preclinical studies.
Q6: What are the common side effects observed in clinical studies?
A6: Mild side effects include nausea, diarrhea, headache, upper respiratory infections, and rare liver enzyme elevation.
Why Choose Us as your Letermovir seller?
- Pharmaceutical-grade Letermovir (≥98% purity)
- Verified by HPLC and MS for consistency
- Ideal for research, preclinical studies, and formulation development
- COA and full analytical documentation available
- Reliable global supply and professional shipping support
certifications
Shipping methods
| Country | Delivery time |
| Untied states | 7-15 DAYS |
| Australia | 7-12 DAYS |
| Germany | 7-12 DAYS |
| Canada | 8-10 DAYS |
| New zealand | 7-10 DAYS |
| Uk | 5-10 DAYS |
| Thailand | 5-8 DAYS |
| Malaysia | 5-8 DAYS |
| Vietnam | 5-8 DAYS |
The delivery time shown above is an estimate. Shipping routes and freight capacity may change from time to time. For the most accurate delivery schedule, please contact us directly.
Payment terms
delivery records
Message us to get your personalized quotation within 24 hours.
-
Whatsapp:+852 6736 4057
-
Telegram:@hinovopept
-
Email:novopept@gmail.com
Hot Tags：letermovir price per kg, letermovir cost comparison, letermovir API sourcing China, where to buy letermovir
letermovir minimum order quantity, letermovir supply chain, letermovir shipping worldwide, etermovir regulatory documents (SPC/MSDS/DMF), letermovir GMP factory China, letermovir spc, letermovir price, letermovir dose, letermovir 480, letermovir tablet
letermovir cmv, letermovir structure, letermovir moa, letermovir iv
Hot Tags: letermovir cas 917389-32-3, China letermovir cas 917389-32-3 manufacturers, suppliers, factory
Send Inquiry
